[{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Cowen","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Brand Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Furosemide","moa":"Sodium\/potassium\/chloride cotransporter 2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Brand Institute","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Brand Institute"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Furosemide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.050000000000000003,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ SVB Securities","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ SVB Securities"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Furosemide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Furosemide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Furosemide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Furosemide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Furosemide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Furosemide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Furosemide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"scPharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Furosemide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"scPharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"scPharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"scPharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Furosemide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"scPharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"scPharmaceuticals \/ Perceptive Advisors","highestDevelopmentStatusID":"14","companyTruncated":"scPharmaceuticals \/ Perceptive Advisors"},{"orgOrder":0,"company":"scPharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Furosemide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"scPharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"scPharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"scPharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by scPharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Furoscix (furosemide) auto-injector is being investigated for the treatment of congestion due to fluid overload in adult patients with NYHA Class IV chronic heart failure.

                          Brand Name : Furoscix

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 12, 2024

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The proceeds will fund company's commercial and development activities for its products, including Furoscix (furosemide), indicated for the treatment of congestion due to fluid overload.

                          Brand Name : Furoscix

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 12, 2024

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Leerink Partners

                          Deal Size : $50.0 million

                          Deal Type : Public Offering

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : The proceeds will fund the ongoing commercialization of Furoscix, the Company’s proprietary formulation of furosemide indicated for the treatment of congestion due to fluid overload in adult patients.

                          Brand Name : Furoscix

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 12, 2024

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Perceptive Advisors

                          Deal Size : $50.0 million

                          Deal Type : Financing

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : SCP-111 is an investigational, low volume, pH neutral formulation of furosemide administered via an autoinjector. It is being evaluated for heart failure.

                          Brand Name : SCP-111

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 12, 2024

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : FDA has accepted for filing the sNDA seeking to expand the FUROSCIX (furosemide injection) indication to include treatment of edema due to fluid overload in patients with chronic kidney disease (CKD).

                          Brand Name : Furoscix

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 25, 2024

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Furoscix (furosemide injection) auto-injector is indicated for congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.

                          Brand Name : Furoscix

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 24, 2024

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Furoscix (furosemide injection) is indicated for the treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.

                          Brand Name : Furoscix

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 19, 2023

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Furoscix® is a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.

                          Brand Name : Furoscix

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 01, 2023

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Furoscix® is a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association (NYHA) Class II and Class III chronic heart failure.

                          Brand Name : Furoscix

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 21, 2023

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Furoscix® (furosemide) primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle.

                          Brand Name : Furoscix

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 30, 2023

                          Lead Product(s) : Furosemide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank